Valion Bio (TIVC) Cash & Equivalents (2021 - 2025)
Valion Bio has reported Cash & Equivalents over the past 5 years, most recently at $12.6 million for Q4 2025.
- For Q4 2025, Cash & Equivalents rose 602.5% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $12.6 million, up 602.5%, while the annual FY2025 figure was $12.6 million, 602.5% up from the prior year.
- Cash & Equivalents for Q4 2025 was $12.6 million at Valion Bio, up from $3.5 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $12.8 million in Q1 2021 and troughed at $700000.0 in Q1 2025.
- A 5-year average of $5.4 million and a median of $3.6 million in 2022 define the central range for Cash & Equivalents.
- Biggest five-year swings in Cash & Equivalents: tumbled 76.01% in 2023 and later soared 602.5% in 2025.
- Year by year, Cash & Equivalents stood at $12.8 million in 2021, then plummeted by 72.51% to $3.5 million in 2022, then fell by 7.79% to $3.2 million in 2023, then plummeted by 44.5% to $1.8 million in 2024, then soared by 602.5% to $12.6 million in 2025.
- Business Quant data shows Cash & Equivalents for TIVC at $12.6 million in Q4 2025, $3.5 million in Q3 2025, and $975000.0 in Q2 2025.